TP53 and metastatic neoplasm: Of the 23 patients (57.5%) who were classified as high risk, 18 had metastatic disease in the brain and/or spine and among them, 7 had other additional high-risk factors including age < 3 years (2 patients), molecular Group 3 (4 patients), and SHH p53 mutant (1 patient).